Sit to Stand test (30 s). | Five times Sit to Stand test | TAMPA total score | IPAQ-SF total score | |||||
---|---|---|---|---|---|---|---|---|
Inactive Participants (n = 174). | p* | r | p* | r | p* | r | p* | r |
Charlson Comorbidity index | 0.001 | -0.264 | 0.005 | 0.227 | 0.002 | 0.239 | 0.020 | -0.184 |
IPAQ-SF total score | < 0.001 | 0.319 | 0.249 | -0.093 | 0.719 | 0.028 | - | 1.000 |
Sit to Stand test (30 s). | - | 1.000 | 0.001 | -0.264 | 0.004 | -0.232 | < 0.001 | 0.319 |
Five times Sit to Stand test | 0.001 | -0.264 | - | 1.000 | < 0.001 | 0.275 | 0.249 | -0.093 |
TAMPA total score | 0.004 | -0.232 | < 0.001 | 0.275 | - | 1.000 | 0.719 | 0.028 |
Active Participants (n = 12). | p | r | p | r | p | r | p | r |
Charlson Comorbidity index | 0.060 | -0.150 | 0.936 | 0.028 | 0.722 | 0.059 | 0.230 | -0.085 |
IPAQ-SF total score | 0.583 | 0.080 | 0.612 | 0.078 | 0.873 | 0.055 | - | 1.000 |
Sit to Stand test (30 s). | - | 1.000 | 0.190 | -0.097 | 0.183 | -0.100 | 0.583 | 0.070 |
Five times Sit to Stand test | 0.190 | -0.097 | - | 1.000 | 0.365 | 0.099 | 0.612 | 0.078 |
TAMPA total score | 0.183 | -0.100 | 0.365 | 0.099 | - | 1.000 | 0.873 | 0.055 |